Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Press Releases
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
Real-time Quote. Real-time Euronext Paris - 10/21 05:38:39 am
19.21 EUR   +6.72%
02:44aVALNEVA : Company Presentation
PU
10/20Top Premarket Gainers
MT
10/18ADRs End Mixed; Valneva, IClick Among Companies Actively Trading
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société VALNEVA SE
02:44aVALNEVA : Company Presentation
PU
10/18VALNEVA : Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Ca..
PU
10/18VALNEVA : COVID-19 vaccine candidate's Phase 3 Topline Results
PU
10/18VALNEVA : Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Ca..
AQ
10/05VALNEVA : to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious ..
PU
10/04VALNEVA : Announces the Cancellation of Ordinary Shares Held by the Company following Term..
AQ
09/30VALNEVA : to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious ..
AQ
09/29VALNEVA : and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, ..
PU
09/28VALNEVA : and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, ..
GL
09/24VALNEVA : Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candi..
PU
09/23Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Cand..
GL
09/17VALNEVA : Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivate..
PU
09/14VACCINE MINISTER : 'We have a right to cancel' the 140m Valneva jabs order
AQ
09/14UK MINISTER : Regulator concern sank deal for Valneva shot
AQ
09/14VALNEVA : Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivate..
GL
09/13VALNEVA : Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Govern..
PU
09/13VALNEVA : Britain ends contract with French startup for vaccines
AQ
09/13VALNEVA : share price plummets after UK government terminates contract
AQ
09/13VALNEVA : Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Govern..
AQ
09/07VALNEVA : Company Presentation – Goldman Sachs Biotech Symposium
PU
09/06VALNEVA : Déclaration d'actions et de droits de vote de la société Valneva SE - Août 2021
GL
09/03VALNEVA : to Participate in Goldman Sachs Eleventh Annual Biotech Symposium (Form 6-K)
PU
09/03VALNEVA : U.S. DoD Exercises First Year Option on IXIARO® Supply Contract
AQ
09/03VALNEVA : U.S. DoD Exercises First Year Option on IXIARO® Supply Contract
GL
09/01VALNEVA : to Participate in Goldman Sachs Eleventh Annual Biotech Symposium
AQ
09/01VALNEVA : Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium
GL
08/23VALNEVA : Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Va..
PU
08/23VALNEVA : Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Va..
GL
08/11VALNEVA : Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
GL
08/10VALNEVA : Reports H1 2021 Financial Results and Provides Business Update (Form 6-K)
PU
08/10VALNEVA : 2021 Half-Year Report
PU
08/10VALNEVA : Reports H1 2021 Financial Results and Provides Business Update
GL
08/05VALNEVA : Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vacci..
AQ
08/05VALNEVA : Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungun..
GL
08/02VALNEVA : Appoints Peter Buhler as Chief Financial Officer (Form 6-K)
PU
07/29VALNEVA : Appoints Peter Buhler as Chief Financial Officer
GL
07/23VALNEVA : and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candid..
PU
07/19VALNEVA : and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candid..
AQ
07/07VALNEVA : Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Can..
AQ
07/07VALNEVA : Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vac..
GL
07/06VALNEVA : Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Jos..
AQ
07/05VALNEVA : to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st Europea..
AQ
07/02VALNEVA : Continues Ongoing Discussions with the European Commission for Inactivated COVID..
PU
07/01VALNEVA : Continues Ongoing Discussions with the European Commission for Inactivated COVID..
GL
06/25VALNEVA : Announces Successful Outcome of its AGM (Form 6-K)
PU
06/24VALNEVA : Presentation – 2021 Combined General Meeting
PU
06/23VALNEVA : Announces Successful Outcome of its AGM
GL
06/11VALNEVA : Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikunguny..
PU
06/11VALNEVA : Announces Termination of Liquidity Contract with Oddo BHF and Natixis and Publis..
AQ
06/10Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungun..
GL
06/07VALNEVA : Déclaration d'actions et de droits de vote de la société Valneva SE – Mai ..
AQ
06/03VALNEVA : Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candida..
GL
06/02VALNEVA : Announces the Availability of Documentation for its Combined General Meeting to ..
AQ
05/20VALNEVA : Q1 2021 Financial Results (unaudited)
PU
05/20Valneva Reports Q1 2021 Financial Results and Business Update
GL
05/20VALNEVA : First quarter results 2021
PU
05/11VALNEVA : Volunteers needed for latest UK COVID-19 vaccine study launched in Surrey
AQ
05/11Valneva Announces Closing of $107.6 million Global Offering
GL
05/10VALNEVA : Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bri..
GL
05/07VALNEVA : Déclaration d'actions et de droits de vote – Avril 2021
GL
05/06VALNEVA : announces trading resumption of its ordinary shares on Euronext Paris
AQ
05/06VALNEVA : announces temporary trading suspension of its ordinary shares on Euronext Paris
GL
05/06Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
GL
05/05VALNEVA : Announces an Indicative Price Range of its Previously Announced Proposed Global ..
GL
04/29VALNEVA : Announces Launch of Proposed Global Offering, Start of the Roadshow and Nasdaq L..
GL
04/27Latest COVID-19 vaccine trial launches in Southampton
AQ
04/21Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vacci..
GL
04/20Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted C..
GL
04/12Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidat..
GL
04/12VALNEVA : Announces Publication of 2020 Universal Registration Document and Provides Busin..
AQ
04/10VALNEVA : Announces Publication of 2020 Universal Registration Document and Provides Busin..
AQ
04/10VALNEVA : Files Registration Statement for Proposed United States Initial Public Offering
AQ
04/06Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccin..
GL
04/06VALNEVA : Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine..
GL
04/02VALNEVA : - Déclaration d'actions et de droits de vote – Mars 2021
GL
1  2  3  4  5  6  7Next
Upcoming event on VALNEVA SE